Prexige

From SourceWatch
Jump to: navigation, search

Prexige (generic name lumiracoxib) is a prescription drug manufactured by Novartis.

In a 2002 interview, Paulo Costa, the head of Novartis Pharmaceuticals in the US, indicated that he thought the osteoarthritis drug could be a major money-spinner for the company. [1] In its 2006 annual report Novartis stated that "as a result of past investments, Novartis has been able to successfully launch a number of new products in 2006" including Prexige. In 2006 Prexige earned $US47 million for the company, a 488% increase on the previous years sales of $8 million. [2]

In August 2007 the Australian Therapeutic Goods Administration withdrew approval for the marketing of the drug due to a number of cases of serious liver side effects experienced by consumers. Use of the drug caused two deaths and necissitated two consumers to require liver transplants.

Company Websites for Prexige

English language sites

Global Website: http://www.prexige.com/
Canada: https://www.prexige.ca/form_en.asp
United Kingdom: http://www.novartis.co.uk/index.shtml

Other Languages

Therapeutic Goods Administration (Australia) Withdrawal Announcements

National Prescribing Service (Australia) Announcements

Company Links & Announcements

US FDA Related Links

Sources

  1. Matthew Herper, "Novartis Looks To Prexige, A New Arthritis Drug", Forbes, April 19, 2002.
  2. "Novartis Group Financial Reprot 2006", Novartis, p.171. (2.3MB Pdf).

External links